Press Releases

 
Press Releases
  Date Title View
Apr 21, 2016
CAMBRIDGE, Mass., April 21, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced positive data from preclinical studies evaluating MM-310, an antibody directed nanotherapeutic (ADN) that encapsulates a newly engineered form of the highly potent chemotherapy docetaxel as a prodrug in an ephrin receptor A2 (EphA2)-targe...
Apr 20, 2016
CAMBRIDGE, Mass., April 20, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its First Quarter 2016 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Monday, May 2. The call will cover an update on Merrimack's progress as well as a summary of first quarter 2016 f...
Apr 14, 2016
NEWCASTLE UPON TYNE, England and CAMBRIDGE, Mass., April 14, 2016 /PRNewswire/ -- Leica Biosystems and Merrimack Pharmaceuticals (NASDAQ: MACK) today announced a strategic partnership to develop companion diagnostic assays to aid in identification of patients who might best respond to current and future oncology therapies developed by Merrimack. Th...
Mar 24, 2016
CAMBRIDGE, Mass., March 24, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the National Comprehensive Cancer Network (NCCN) has included ONIVYDE® (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin in its 2016 Clinical Practice Guidelines in Oncology for pancreatic adenoca...
Mar 16, 2016
CAMBRIDGE, Mass., March 16, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data on its extensive oncology pipeline at the 2016 American Association for Cancer Research (AACR) Annual Meeting, April 16-20, 2016 at the Ernest N. Morial Convention Center, New Orleans, Lo...
Feb 25, 2016
CAMBRIDGE, Mass., Feb. 25, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its fourth quarter and full year 2015 financial results. Merrimack will host a live conference call and webcast today, Thursday, February 25 at 4:30 p.m., Eastern time, to provide an update on Merrimack's progress as well as a summary of t...
Feb 17, 2016
CAMBRIDGE, Mass., Feb. 17, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK)  today announced that the company will host its Fourth Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Thursday, February 25. The call will cover an update on Merrimack's progress as well as a summary of fourth quar...
Jan 19, 2016
CAMBRIDGE, Mass., Jan. 19, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that an updated overall survival analysis of the Phase 3 NAPOLI-1 study of ONIVYDE® (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin achieved a substantial improvement in 12-month overall survival...
Jan 11, 2016
CAMBRIDGE, Mass., Jan. 11, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that an additional overall survival analysis from the Phase 3 NAPOLI-1 study of ONIVYDE™ (irinotecan liposome injection), also known as "nal-IRI," in post-gemcitabine metastatic pancreatic cancer will be presented at the American Soc...
Jan 5, 2016
CAMBRIDGE, Mass., Jan. 5, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President and CEO, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 at 2:30 p.m. (PT) at the Westin St. Francis Hotel in San Francisco. A live webcast of th...
1
...
NextLast
= add release to Briefcase